Phase 1 clinical study begins for VTP-300 Immunotherapeutic for Hepatitis B patients Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020 using the complete…
